Subtopic Deep Dive
ALK Rearrangements and Inhibitors
Research Guide
What is ALK Rearrangements and Inhibitors?
ALK rearrangements in lung cancer refer to EML4-ALK fusion genes driving 5% of non-small cell lung cancer (NSCLC) cases, targeted by tyrosine kinase inhibitors like crizotinib, alectinib, and brigatinib.
EML4-ALK fusions activate oncogenic signaling in NSCLC, treatable with first-generation inhibitor crizotinib followed by next-generation agents overcoming resistance (Peters et al., 2017; Gainor et al., 2016). Clinical trials demonstrate superior progression-free survival with alectinib and brigatinib over crizotinib in untreated ALK-positive NSCLC (Camidge et al., 2018). Over 10,000 citations across key papers highlight sequencing strategies and resistance mechanisms.
Why It Matters
ALK inhibitors achieve 70-80% response rates in ALK-positive NSCLC, enabling precision oncology for 5% of patients and extending survival by years (Peters et al., 2017; Camidge et al., 2018). They exemplify biomarker-driven therapy, reducing reliance on chemotherapy and improving brain metastasis control (Gainor et al., 2016). NCCN guidelines integrate these agents as first-line standards, influencing global treatment protocols (Ettinger et al., 2019; Ettinger et al., 2021).
Key Research Challenges
Acquired Resistance Mechanisms
Second-generation ALK inhibitors like alectinib face resistance via ALK mutations such as G1202R and F1174V (Gainor et al., 2016; Katayama et al., 2014). Secondary pathway activations compound progression after crizotinib. Novel mutations require sequencing for third-generation options.
Brain Metastases Penetration
Crizotinib shows limited CNS efficacy, while alectinib and brigatinib improve intracranial responses in trials (Peters et al., 2017; Camidge et al., 2018). Optimizing blood-brain barrier crossing remains critical for 40% of patients with metastases.
Fusion Variant Heterogeneity
Diverse EML4-ALK variants influence inhibitor sensitivity, detected via next-generation sequencing (Ou et al., 2014). Standardization of testing lags behind therapy evolution (Awad and Shaw, 2014).
Essential Papers
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
A view on drug resistance in cancer
Neil Vasan, José Baselga, David M. Hyman · 2019 · Nature · 2.6K citations
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · 2017 · New England Journal of Medicine · 2.4K citations
As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02...
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard, Egbert F. Smit, Harry J.M. Groen et al. · 2017 · The Lancet Oncology · 1.3K citations
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer
Justin F. Gainor, Leila Dardaei, Satoshi Yoda et al. · 2016 · Cancer Discovery · 1.1K citations
Abstract Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhib...
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al. · 2019 · Journal of the National Comprehensive Cancer Network · 994 citations
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update,...
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · 2021 · Journal of the National Comprehensive Cancer Network · 986 citations
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recen...
Reading Guide
Foundational Papers
Start with Awad and Shaw (2014) for crizotinib basics and Katayama et al. (2014) for early resistance, establishing ALK TKI sequencing principles.
Recent Advances
Peters et al. (2017, ALEX trial) and Camidge et al. (2018, brigatinib) for first-line efficacy; Ettinger et al. (2021) NCCN for current standards.
Core Methods
NGS for fusion/variant detection (Ou et al., 2014), clinical trials for PFS/OS (Peters 2017), cell line models for resistance (Gainor 2016).
How PapersFlow Helps You Research ALK Rearrangements and Inhibitors
Discover & Search
Research Agent uses searchPapers and citationGraph to map 2,374-cited ALEX trial (Peters et al., 2017) to brigatinib studies (Camidge et al., 2018), revealing 935-cited progression-free survival data; exaSearch uncovers resistance papers like Gainor et al. (2016) beyond top results; findSimilarPapers links foundational mutations (Katayama et al., 2014).
Analyze & Verify
Analysis Agent applies readPaperContent to extract resistance mutations from Gainor et al. (2016), verifies claims with CoVe against NCCN guidelines (Ettinger et al., 2021), and runs PythonAnalysis on trial data for GRADE-assessed survival curves (e.g., HR=0.47 from Peters et al., 2017) with statistical tests.
Synthesize & Write
Synthesis Agent detects gaps in resistance sequencing post-alectinib (Gainor et al., 2016), flags contradictions between trials; Writing Agent uses latexEditText, latexSyncCitations for review manuscripts, latexCompile for figures, exportMermaid for inhibitor resistance pathway diagrams.
Use Cases
"Statistical comparison of PFS hazard ratios in ALEX vs. brigatinib trials for ALK NSCLC."
Research Agent → searchPapers('ALEX brigatinib PFS') → Analysis Agent → runPythonAnalysis(pandas on extracted HRs from Peters 2017, Camidge 2018) → GRADE-verified table output with p-values.
"Draft LaTeX review section on ALK inhibitor sequencing with citations."
Synthesis Agent → gap detection (post-crizotinib options) → Writing Agent → latexEditText('ALK sequencing') → latexSyncCitations([Peters 2017, Gainor 2016]) → latexCompile → PDF review section.
"Find open-source NGS analysis code for ALK fusion detection from papers."
Research Agent → paperExtractUrls(Gainor 2016) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified Python scripts for variant calling.
Automated Workflows
Deep Research workflow scans 50+ ALK papers via citationGraph from Hirsch et al. (2016), producing structured reports on inhibitor evolution (Peters 2017 → Camidge 2018). DeepScan applies 7-step CoVe to verify resistance claims (Gainor 2016) with GRADE scoring. Theorizer generates hypotheses on novel inhibitors from mutation patterns (Katayama 2014).
Frequently Asked Questions
What defines ALK rearrangements in NSCLC?
ALK rearrangements are EML4-ALK fusions in 5% of NSCLC, detected by FISH or NGS, driving oncogenesis (Awad and Shaw, 2014).
What are key ALK inhibitors and their sequence?
Crizotinib first-line, followed by alectinib or brigatinib; NCCN recommends based on ALEX and ALTA-1L trials (Peters et al., 2017; Camidge et al., 2018; Ettinger et al., 2021).
Name seminal papers on ALK resistance.
Gainor et al. (2016, 1115 citations) details mechanisms to second-generation inhibitors; Katayama et al. (2014) identifies alectinib-specific mutations.
What open problems exist in ALK therapy?
Overcoming G1202R resistance and improving CNS penetration beyond brigatinib; third-generation inhibitors needed (Ou et al., 2014).
Research Lung Cancer Treatments and Mutations with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching ALK Rearrangements and Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers